Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Short-term Investments (2019 - 2022)

ADC Therapeutics has reported Short-term Investments over the past 4 years, most recently at $79949.5 for Q4 2022.

  • Quarterly results put Short-term Investments at $79949.5 for Q4 2022, down 4.29% from a year ago — trailing twelve months through Dec 2022 was $79949.5 (down 4.29% YoY), and the annual figure for FY2022 was $79949.5, down 4.29%.
  • Short-term Investments reached $79949.5 in Q4 2022 per ADCT's latest filing, down from $83529.4 in the prior quarter.
  • Across five years, Short-term Investments topped out at $85197.2 in Q4 2020 and bottomed at $77820.8 in Q4 2019.
  • Median Short-term Investments over the past 4 years was $81739.5 (2021), compared with a mean of $81624.2.
  • The largest annual shift saw Short-term Investments rose 9.48% in 2020 before it decreased 4.29% in 2022.
  • Over 4 years, Short-term Investments stood at $77820.8 in 2019, then increased by 9.48% to $85197.2 in 2020, then fell by 1.96% to $83529.4 in 2021, then dropped by 4.29% to $79949.5 in 2022.
  • Business Quant data shows Short-term Investments for ADCT at $79949.5 in Q4 2022, $83529.4 in Q4 2021, and $85197.2 in Q4 2020.